Bolivia Medical Device Definition and Scope: The Anexo 2 Grouping Logic

1. Key takeaways

Bolivia has no standalone definition article for medical devices. The term dispositivos médicos appears as a regulated product category in the list of the scope of application in Article 2 of Ley N° 1737 of December 17, 1996, and its concrete boundaries are drawn jointly by the purpose clause in Section 1.2 of the Medical Device Sanitary Registration Manual and by the grouping table in Anexo 2 of the same manual. The same article of the law also lists diagnostic and clinical laboratory reagents and dental products, among others. The working test applied by GRZAN is as follows: any product that falls within a group of the Anexo 2 grouping table and whose intended use is directed at diagnosis, monitoring, treatment, or replacement in the human body should be filed as a device. Where the boundary is ambiguous, the manual’s grouping table, not the classification catalogs of the Chinese mainland, the European Union, or any third market, is the reference that decides.

The absence of a standalone definition clause has a practical side effect: the scope of the Bolivian system is learned by reading the grouping table rather than by parsing a definition. That makes the manual, and specifically Anexo 2, the single most consulted document in the early phase of a Bolivian project, before any dossier work begins. Product managers should expect to spend real time in Anexo 2, mapping each catalog item to a group and recording the mapping with a rationale, because the same mapping later drives the number of registrations, the fee calculation under the current fee schedule, and the structure of the submission calendar.

2. Legal basis

3. Expert insights

Insight one: contact with the human body is not the only criterion for falling into scope. Some public summaries describe the Bolivian scope as devices that contact the human body plus biomedical equipment and accessories. Compared with the three families of the Anexo 2 grouping table (non-invasive, invasive, and active devices), that summary is far too coarse. The grouping logic of the manual is structural, organized by families and groups rather than by a binary of contact versus no contact, so a product can be regulated even where the contact-based description would suggest otherwise.

Insight two: in vitro diagnostic reagents sit inside the same system but on a separate signal line. Judging by the product signal distribution in the official weekly reports of AGEMED, device signals and in vitro diagnostic reagent signals are two parallel major categories, which shows that IVD products are handled as an independent product line in practice. Companies preparing catalog mappings should therefore keep IVD as a separate line item, with its own documentation templates and naming conventions, instead of blending it into the device list.

Insight three: accessories and spare parts are not exempt from filing. Section 2.9 of the manual imposes commitments on spare parts and maintenance for biomedical equipment, and at the import stage Form 011 also requires technical description sheets for biomedical equipment, accessories, and spare parts. The judgment that an accessory needs no registration because it is an accessory does not stand in Bolivia. The correct approach is to confirm whether the accessory is already covered by the group of the main equipment, and if not, to plan a separate filing.

Insight four: intended use wording decides scope questions faster than product design does. In borderline cases, the deciding element is rarely the engineering of the device but the claim written on the label and in the instructions for use. A product whose stated purpose points to diagnosis, monitoring, treatment, or replacement in the human body pulls itself into the device regime regardless of how innocuous its design looks, while the same hardware described as a general-purpose laboratory or industrial instrument may sit outside the grouping table altogether. This is why the intended use statement, the Spanish-language label, and the grouping rationale must be written as one consistent text, checked against each other before submission rather than reconciled after an observation.

4. Practical recommendations

The three recommendations below all serve one purpose: to keep the scope determination anchored in Bolivian sources. Mapping products against foreign classification systems feels efficient because those catalogs are familiar, but every mapping decision eventually has to be defended against Anexo 2, and a mapping made on a foreign basis usually has to be redone. Doing the mapping once, on the Bolivian basis, with the rationale recorded, is the cheaper path even if it is slower on the first day.

One further practical note: the grouping table should be re-consulted whenever the product line changes, not only at first entry. New models, new accessories, and new combinations can move items between groups, and a mapping that was correct at launch can drift out of date as the catalog evolves. A short annual review of the mapping, checked against the manual version in force, keeps the registration portfolio aligned with the product portfolio without requiring a full re-analysis.

1. Use the Anexo 2 grouping table as the first reference for scope determination. Do not reason backwards from the classification catalog of the Chinese mainland or from the classification rules of the EU MDR.
2. Manage IVD and devices as separate lines, maintaining documentation templates and naming code systems independently.
3. For accessories, first ask whether they belong to the same group. Same-group accessories may be handled together with the main equipment; different-group accessories require a separate case.

5. Verification checklist

• □ Can the target product be matched to a group within the three families of Anexo 2
• □ Is the statement of intended use consistent with the Spanish-language label
• □ Has a separate documentation line been established for IVD products
• □ Are accessories and spare parts covered by the main equipment registration, or do they need a separate case
• □ Does the product also need to be handled as a diagnostic and clinical laboratory reagent

Regulatory information verified as of October 29, 2026.

GRZAN supports manufacturers, importers, and authorized representatives with medical device registration in Bolivia, covering dossier preparation, local entity coordination, and regulatory strategy. Contact info@grzanglobal.com for project inquiries.